IDPDL1 is an AstraZeneca  site providing references and educational material for healthcare professionals interested in PD-L1 testing.

Over recent years, there has been increased interest in the potential use of biomarkers in cancer.PD-L1 is one such biomarker. The aim of iD PD-L1 is to provide information for pathologists on PD-L1 expression testing, including: the pre-analytical stages, the practicalities of using, reading, interpreting and reporting PD-L1 assays, and training/quality control measures https://www.idpdl1.com/home.html

Professor Patrick Pauwels discusses the role of PD-L1 testing for immunotherapy in a short video. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of disease progression.

Watch the video with Prof. Pauwels

Rudy Hovelinck
Diagnostics Manager at AstraZeneca

NS ID BE-1676-RD09/2018-LB

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.